Company Profile
Madrigal Stock Price, News & Analysis
- Ticker:
- MDGL
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
510.36 USD (-0.73%)
Close
Last updated: August 6, 2026
10.4B USD
Market cap
Why the stock is moving
The latest monitored company update is “Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4).” The corresponding closing-price reaction is not yet available.
Company overview
Commercial MASH Leader
Madrigal Pharmaceuticals is a biopharmaceutical company focused on metabolic dysfunction-associated steatohepatitis, or MASH. Its lead product, Rezdiffra, is a once-daily oral liver-directed THR-beta agonist and the first medicine approved by both the FDA and European Commission for MASH with moderate to advanced fibrosis.
Rezdiffra Growth Platform
Rezdiffra is the company's commercial foundation. Second-quarter 2026 net sales reached $364.3 million, up 71% year over year, and more than 49,000 patients were on therapy as of June 30, 2026. Madrigal is investing in field-force expansion, disease education, real-world evidence, and physician adoption to maximize the long-term value of the launch.
Pipeline Anchored by Combination Therapy
Madrigal is building beyond Rezdiffra through MGL-2086, an oral small-molecule GLP-1 receptor agonist and orforglipron derivative. The company initiated Phase 1 dosing in June 2026 as part of a strategy to develop once-daily oral combination treatments for MASH anchored by Rezdiffra.
Strategic Position
Madrigal is best understood as a commercial-stage MASH company with a foundational therapy and a strategy to defend leadership through IP, evidence generation, and combination development. Its differentiation rests on Rezdiffra's first-mover position, expanding patient base, and potential to address both liver and cardiometabolic risk.
Future catalysts
Phase 1 safety and dose-response evaluation for MGL-2086 after first dosing in June 2026.
Future data from the Phase 3 outcomes trial of Rezdiffra in compensated MASH cirrhosis.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Madrigal (MDGL)?
Madrigal (MDGL) most recently closed at 510.36 USD, a -0.73% move versus the previous session.
What is the market cap of Madrigal (MDGL)?
Madrigal currently has a market capitalization of 10.4B USD on BioPharmSignal.
What does Madrigal do?
Commercial MASH Leader Madrigal Pharmaceuticals is a biopharmaceutical company focused on metabolic dysfunction-associated steatohepatitis, or MASH. Its lead product, Rezdiffra, is a once-daily oral liver-directed THR-beta agonist and the first medicine approved by both the FDA and European Commission for MASH with moderate to advanced fibrosis. Rezdiffra...
On which exchange is MDGL stock listed?
Madrigal (MDGL) is associated with NASDAQ, United States, Biopharma.
What is MGL-2086?
Phase 1 safety and dose-response evaluation for MGL-2086 after first dosing in June 2026.
Which conditions is Madrigal targeting with MGL-2086?
Madrigal is associated with metabolic disease based on its company overview and current catalyst commentary.
How does Madrigal describe recent progress with MGL-2086?
Phase 1 safety and dose-response evaluation for MGL-2086 after first dosing in June 2026.
What is GLP-1?
Pipeline Anchored by Combination Therapy Madrigal is building beyond Rezdiffra through MGL-2086, an oral small-molecule GLP-1 receptor agonist and orforglipron derivative.